GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer
GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal worth up to £268 million.
GlaxoSmithKline (GSK) has struck a deal to acquire exclusive rights to develop and commercialise an antibody-drug conjugate (ADC) from Syndivia, targeting metastatic castration-resistant prostate cancer.
- The agreement is reported to be worth up to £268 million.
- The therapy addresses a significant unmet need given the limited targeted treatment options for this advanced form of prostate cancer.
Syndivia's candidate delivered enhanced tumour reduction in preclinical studies while maintaining an encouraging safety profile.
GSK's acquisition reinforces its oncology pipeline and gives Syndivia the scale to progress its promising asset.
Author's summary: GSK acquires rights to Syndivia's ADC asset.